The University of Maryland School of Medicine (UMSOM) Center for Vaccine Development and Global Health (CVD) has been an established VTEU site since 1974. The goal of the VTEUs is to initiate innovative concepts for clinical research and implement clinical site protocols for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, and devices for the treatment and prevention of infectious diseases, and CVD is uniquely poised to accomplish this goal. Under the current VTEU contract, CVD was awarded over 18 Task Orders, enrolled over 700 participants, and successfully collaborated with national and international sites. With this application for renewed funding, CVD has again assembled an expert and accomplished investigative team with complementary skill sets in all areas necessary to address the NIAID priority areas. Our technical capacities are complemented by effective and proven leadership of large contracts and initiatives; extensive clinical research experience, including performance of clinical trials in all phases of development and human challenge studies; in-depth subject matter expertise in NIAID priority areas; an accomplished record in training fellows and junior faculty in clinical research; a robust and innovative project management plan; and a cohesive, collaborative approach to working with the Leadership Group (LG), NIAID, other VTEUs and other partners. We have access to state-of-the art clinical and laboratory facilities, including two large inpatient units where human challenge studies are routinely conducted. This proposal describes in further detail our team?s ability to work closely and collaboratively with the LG and NIAID to quickly and cost-efficiently develop concepts, protocols, study designs and proposal plans, and to maintain a flexible infrastructure that can respond with agility to evolving research priorities and public health emergencies requiring large numbers of volunteers. We will incorporate new data as they become available, modify our work to align with these new data and respond rapidly to evolving research priorities. Our broad involvement with advisory committees that address research priorities and public policy enables us to bring the highest priority and most innovative questions to the LG.

Public Health Relevance

Advancing vaccines, treatments, and other tools for preventing and controlling endemic, epidemic and emerging infectious diseases that threaten health and well-being is a top NIAID and public healthy priority. In its capacity as a longstanding and accomplished VTEU, the University of Maryland Center for Vaccine Development and Global Health (CVD) proposes to harness our innovation, technical capacity, in-depth subject matter expertise, and broad network of domestic and international collaborators to achieve program goals. We will work collaboratively with VTEU sites and leadership to identify and implement the highest quality clinical research across NIAID priority areas, while mentoring and developing the next generation of clinical scientists.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Lee, Marina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Medicine
United States
Zip Code